Considering that neither oxidative stress nor mitochondrial biogenesis serves as a pathway for SIRT6 in combating cholestatic liver disease, we theorized that the inhibition of bile acid synthesis might be the key mechanism underlying SIRT6's therapeutic function. Here, SIRT6 is linked to Cholestatic liver disease.